Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Has results × tilsotolimod × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 449 Bevacizumab 438 Carboplatin 378 Paclitaxel 333 Gemcitabine 323 Cisplatin 314 pembrolizumab 313 Docetaxel 284 Rituximab 281 Radiotherapy 269 Nivolumab 210 Doxorubicin 210 Dexamethasone 206 Fluorouracil 202 Capecitabine 191 Oxaliplatin 189 Erlotinib Hydrochloride 176 fludarabine phosphate 172 Etoposide 165 Pemetrexed 157 Cetuximab 154 Bortezomib 153 Lenalidomide 152 Leucovorin 150 Trastuzumab 148 Filgrastim 148 fludarabine 147 Irinotecan 146 Prednisone 144 Cytarabine 143

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02644967 2022-08-03

ILLUMINATE-204

Idera Pharmaceuticals, Inc.

Phase 2 Completed

53 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡